
Aktuelle Studien zum Urothel- und Harnblasenkarzinom
Sie befinden sich hier:
Studientitel |
Status |
Seit |
Medikation |
PROOF 302 Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302) |
Aktiv |
20.10.2020 Rekrutierung aktiv |
Infigratinib |
Basilea DZB-CS-201 An open-label multi-cohorte Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02) |
Aktiv |
08.06.2020 |
|
MK-3475-866 / KEYNOTE 866 Peri-operative Pembrolizumab + Neoadjuvant Chemotherapv vs Periop. Placebo + Neoadjuvant Chemotherapy in Cisplatin Eligible Patients with Muscle-Invasive Bladder Cancer |
Aktiv |
19.12.2019 Rekrutierung aktiv |
Peri-operative Pembrolizumab + Neoadjuvant Chemotherapv vs Periop. Placebo + Neoadjuvant Chemotherapy |
POTOMAC: Phase III Randomized, Open-label, Multi-center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as Combination Therapy versus BCG alone in High Risk, BCG-Naïve Non-muscle-Invasive Bladder Cancer Patients |
Aktiv |
Rekrutierung abgeschlossen |
Durvalumab and BCG vs BCG alone |
NKTR-214 Eine randomisierte, nicht vergleichende, unverblindete Studie der Phase 2 zu NKTR-214 in Kombination mit Nivolumab und zu Chemotherapie bei Patienten mit lokal fortgeschrittenem oder metastasierendem Urothelkarzinom mit niedriger PD-L1-Expression, die für eine Cisplatin-Therapie nicht geeignet sind |
Aktiv |
Rekrutierung abgeschlossen |
|
Incyte - A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations |
Aktiv |
Rekrutierung abgeschlossen |
Tyrosine Kinase Inhibitor INCB054828 |
Immunomedics: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer” Protocol: IMMU-132-13 |
In Planung |
||
Cabopoint: Ipsen, Protocol number F-FR-60000-023: A Phase II, Multicentre, Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a clear-cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors (Parexel Project No. 243458) |
In Planung |
||
SGN22E-003 An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer |
In Planung |
||
Ansprechpartner |
|||
Sektionsleiterin PD Dr. M. De Santis, OÄ Dr. U. Steiner, A. Biniszkiewicz, Tel.: Tel.: 030-450 615092, Fax: 030-450 7515927 |